2026 Global: Active Implanted Medical Devices-Competitive Review (2032) report
Description
The 2026 Global: Active Implanted Medical Devices-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for active implanted medical devices by geography and historical trend. The scope of the report extends to sizing of the active implanted medical devices market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Medtronic PLC dominates the active implantable medical devices market, holding a leading position alongside Boston Scientific Corporation and Abbott Laboratories, which together command approximately 95% of the industry share. These giants innovate in pacemakers, implantable cardioverter defibrillators (ICDs), and neurostimulators, driven by rising chronic diseases like cardiovascular and neurological disorders. Boston Scientific excels in stents, neuromodulation devices, and deep brain stimulators for Parkinson's therapy, leveraging AI-enabled remote monitoring to enhance patient outcomes. Abbott Laboratories advances cardiac rhythm management with wireless-connected ICDs and pacemakers, benefiting from strong U.S. reimbursement policies that cover most implants. BIOTRONIK SE & Co. KG specializes in compact cardiac devices and bioresorbable materials, while LivaNova PLC focuses on neuromodulation for epilepsy and heart failure therapies. Cochlear Ltd. leads in auditory implants, providing cochlear devices that restore hearing for millions globally.
Expanding the roster, Sonova Holding AG (via Advanced Bionics) and MED-EL GmbH innovate in hearing implants, integrating IoT for real-time adjustments and telehealth compatibility. LivaNova and BIOTRONIK extend into ventricular assist devices and neuromodulators, addressing heart failure and chronic pain amid aging populations in North America and Japan. Johnson & Johnson enters through cardiovascular implants like defibrillators, bolstered by acquisitions and R&D investments nearing 20% growth, positioning it to challenge top ranks. Nevro Corp. pioneers high-frequency spinal cord stimulation for intractable pain, while Axonics Inc. targets sacral neuromodulation for urinary dysfunction, capturing niche markets with minimally invasive solutions. These firms fuel market growth from USD 27.65 billion in 2025 to USD 44.94 billion by 2033 at a 7.2% CAGR, propelled by 3D printing and AI integration.
North America leads with over 33% share, anchored by these companies' R&D hubs and high arrhythmia prevalence affecting 12 million Americans annually. Europe follows at 28.4%, with frequent launches from Boston Scientific and Abbott, while Asia-Pacific surges via investments in China and India. Competition remains intense, with mergers like Johnson & Johnson's Shockwave acquisition enhancing portfolios in smart implants. MicroPort CRM and Terumo contribute compact pacemakers and CRM devices, emphasizing biocompatibility for longevity. Hospitals dominate end-use at 7.8% CAGR, as infrastructure expands globally under initiatives like India's Ayushman Bharat. This landscape underscores relentless innovation, ensuring accessible therapies for chronic conditions worldwide.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for active implanted medical devices by geography and historical trend. The scope of the report extends to sizing of the active implanted medical devices market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Medtronic PLC dominates the active implantable medical devices market, holding a leading position alongside Boston Scientific Corporation and Abbott Laboratories, which together command approximately 95% of the industry share. These giants innovate in pacemakers, implantable cardioverter defibrillators (ICDs), and neurostimulators, driven by rising chronic diseases like cardiovascular and neurological disorders. Boston Scientific excels in stents, neuromodulation devices, and deep brain stimulators for Parkinson's therapy, leveraging AI-enabled remote monitoring to enhance patient outcomes. Abbott Laboratories advances cardiac rhythm management with wireless-connected ICDs and pacemakers, benefiting from strong U.S. reimbursement policies that cover most implants. BIOTRONIK SE & Co. KG specializes in compact cardiac devices and bioresorbable materials, while LivaNova PLC focuses on neuromodulation for epilepsy and heart failure therapies. Cochlear Ltd. leads in auditory implants, providing cochlear devices that restore hearing for millions globally.
Expanding the roster, Sonova Holding AG (via Advanced Bionics) and MED-EL GmbH innovate in hearing implants, integrating IoT for real-time adjustments and telehealth compatibility. LivaNova and BIOTRONIK extend into ventricular assist devices and neuromodulators, addressing heart failure and chronic pain amid aging populations in North America and Japan. Johnson & Johnson enters through cardiovascular implants like defibrillators, bolstered by acquisitions and R&D investments nearing 20% growth, positioning it to challenge top ranks. Nevro Corp. pioneers high-frequency spinal cord stimulation for intractable pain, while Axonics Inc. targets sacral neuromodulation for urinary dysfunction, capturing niche markets with minimally invasive solutions. These firms fuel market growth from USD 27.65 billion in 2025 to USD 44.94 billion by 2033 at a 7.2% CAGR, propelled by 3D printing and AI integration.
North America leads with over 33% share, anchored by these companies' R&D hubs and high arrhythmia prevalence affecting 12 million Americans annually. Europe follows at 28.4%, with frequent launches from Boston Scientific and Abbott, while Asia-Pacific surges via investments in China and India. Competition remains intense, with mergers like Johnson & Johnson's Shockwave acquisition enhancing portfolios in smart implants. MicroPort CRM and Terumo contribute compact pacemakers and CRM devices, emphasizing biocompatibility for longevity. Hospitals dominate end-use at 7.8% CAGR, as infrastructure expands globally under initiatives like India's Ayushman Bharat. This landscape underscores relentless innovation, ensuring accessible therapies for chronic conditions worldwide.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.